Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways shares surged Tuesday after the company said its psilocybin therapy for depression met its primarily goals in recent trials. Shares traded 34% higher ahead of the morning bell at ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the ...